Laval, Canada Clinical Trials
A listing of Laval, Canada clinical trials actively recruiting patients volunteers.
Found 45 clinical trials
Pompe Disease Registry
The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …
- 0 views
- 19 Feb, 2024
- +190 other locations
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort
The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls The overall goal of …
- 0 views
- 19 Feb, 2024
- +45 other locations
Cell-free DNA in Hereditary And High-Risk Malignancies
The goal of this study is to develop an effective, sensitive blood test that can detect early tumours in patients with known or suspected hereditary cancer syndromes (HCS). If this new blood test is accurate, it could be used to screen patients for cancer and allow for earlier cancer detection. …
- 0 views
- 19 Feb, 2024
- +6 other locations
First Level Socio-geriatric Evaluation: ESOGER Databank
Coronavirus disease 2019 (COVID-19) is an infectious disease. Physical distancing is one of the most effective ways to reduce the spread of COVID-19, but this key prevention intervention may have adverse consequences on older adults living at home. Screening older adults living at home and at risk for adverse consequences …
- 0 views
- 19 Feb, 2024
- 1 location
Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population
Introduction: Second Generation Antipsychotics (SGAs) are widely used in the pediatric population. It is currently established that SGAs may induce undesirable metabolic adverse events (AEs) such as weight gain, metabolic changes in blood lipids or glucose with risk of potential cardiovascular morbidity and mortality. The Canadian Alliance for Monitoring Effectiveness …
- 0 views
- 19 Feb, 2024
- 1 location